AU2016304464B2 - Pyrazole pyrimidine derivative and uses thereof - Google Patents
Pyrazole pyrimidine derivative and uses thereof Download PDFInfo
- Publication number
- AU2016304464B2 AU2016304464B2 AU2016304464A AU2016304464A AU2016304464B2 AU 2016304464 B2 AU2016304464 B2 AU 2016304464B2 AU 2016304464 A AU2016304464 A AU 2016304464A AU 2016304464 A AU2016304464 A AU 2016304464A AU 2016304464 B2 AU2016304464 B2 AU 2016304464B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mmol
- cancer
- mixture
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021200839A AU2021200839A1 (en) | 2015-08-04 | 2021-02-10 | Pyrazole pyrimidine derivative and uses thereof |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200846P | 2015-08-04 | 2015-08-04 | |
| US62/200,846 | 2015-08-04 | ||
| US201562268750P | 2015-12-17 | 2015-12-17 | |
| US62/268,750 | 2015-12-17 | ||
| PCT/IL2016/050852 WO2017021969A1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021200839A Division AU2021200839A1 (en) | 2015-08-04 | 2021-02-10 | Pyrazole pyrimidine derivative and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016304464A1 AU2016304464A1 (en) | 2018-02-22 |
| AU2016304464B2 true AU2016304464B2 (en) | 2020-11-19 |
Family
ID=56738143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016304464A Active AU2016304464B2 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
| AU2021200839A Abandoned AU2021200839A1 (en) | 2015-08-04 | 2021-02-10 | Pyrazole pyrimidine derivative and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021200839A Abandoned AU2021200839A1 (en) | 2015-08-04 | 2021-02-10 | Pyrazole pyrimidine derivative and uses thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10376511B2 (OSRAM) |
| EP (1) | EP3331877B1 (OSRAM) |
| JP (1) | JP7083309B2 (OSRAM) |
| KR (1) | KR102698366B1 (OSRAM) |
| CN (1) | CN108137562B (OSRAM) |
| AU (2) | AU2016304464B2 (OSRAM) |
| CA (1) | CA2994644A1 (OSRAM) |
| CY (1) | CY1124898T1 (OSRAM) |
| DK (1) | DK3331877T3 (OSRAM) |
| ES (1) | ES2901349T3 (OSRAM) |
| HR (1) | HRP20211949T1 (OSRAM) |
| HU (1) | HUE057607T2 (OSRAM) |
| IL (1) | IL257282B (OSRAM) |
| LT (1) | LT3331877T (OSRAM) |
| MX (1) | MX384172B (OSRAM) |
| PL (1) | PL3331877T3 (OSRAM) |
| PT (1) | PT3331877T (OSRAM) |
| RS (1) | RS62728B1 (OSRAM) |
| RU (1) | RU2735522C2 (OSRAM) |
| SI (1) | SI3331877T1 (OSRAM) |
| SM (1) | SMT202100720T1 (OSRAM) |
| WO (1) | WO2017021969A1 (OSRAM) |
| ZA (1) | ZA201800671B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3331877T3 (da) * | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pyrazolpyrimidinderivat og anvendelser deraf |
| ES2902885T3 (es) * | 2017-02-01 | 2022-03-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| MX2020008375A (es) | 2018-02-08 | 2020-09-25 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Compuestos de heteroarilo, composiciones farmaceuticas de los mismos y su uso terapeutico. |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| BR112021024330A2 (pt) * | 2019-06-03 | 2022-01-11 | Biotheryx Inc | Sais cristalinos não higroscópicos de um composto de pirazol, e composições farmacêuticas e uso dos mesmos |
| CN114127058B (zh) * | 2019-07-04 | 2024-06-25 | 深圳国顺康医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| PH12022550361A1 (en) | 2019-08-14 | 2023-02-27 | Incyte Corp | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| JP7693656B2 (ja) | 2019-10-11 | 2025-06-17 | インサイト・コーポレイション | Ｃｄｋ２阻害剤としての二環式アミン |
| WO2021146220A1 (en) * | 2020-01-13 | 2021-07-22 | Biotheryx, Inc. | Pyrazolylpyrimidines and use thereof |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| BR112022019155A2 (pt) * | 2020-03-26 | 2022-12-06 | Janssen Pharmaceutica Nv | Aril piperidinas como moduladores da monoacilglicerol lipase |
| WO2022204220A1 (en) * | 2021-03-24 | 2022-09-29 | Biotheryx, Inc. | Pyrazolylpyrimidines for treating malignant solid tumor |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11752151B2 (en) | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2025199440A1 (en) * | 2024-03-21 | 2025-09-25 | Edgewood Oncology | Methods of treating liposarcoma using a pyrazole compound |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015058140A1 (en) * | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03005001A (es) | 2000-12-05 | 2003-09-05 | Vertex Pharma | Inhibidores de n- terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
| CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| ZA200607639B (en) | 2004-03-30 | 2008-05-28 | Taisho Pharmaceutical Co Ltd | Pyrimidine derivatives and methods of treatment related to the use thereof |
| JP2007145819A (ja) | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| WO2007138277A1 (en) | 2006-05-26 | 2007-12-06 | Astrazeneca Ab | 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation |
| ATE524459T1 (de) | 2007-12-07 | 2011-09-15 | Novartis Ag | Pyrazolederivate und ihr einsatz als hemmer von cyclinabhängigen kinasen |
| EP2776432B1 (en) | 2011-11-04 | 2017-03-29 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
| RU2016110852A (ru) * | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
| DK3331877T3 (da) | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pyrazolpyrimidinderivat og anvendelser deraf |
| ES2902885T3 (es) * | 2017-02-01 | 2022-03-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer |
| MX2020008375A (es) | 2018-02-08 | 2020-09-25 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Compuestos de heteroarilo, composiciones farmaceuticas de los mismos y su uso terapeutico. |
-
2016
- 2016-08-04 DK DK16753709.1T patent/DK3331877T3/da active
- 2016-08-04 PT PT167537091T patent/PT3331877T/pt unknown
- 2016-08-04 RS RS20211558A patent/RS62728B1/sr unknown
- 2016-08-04 SM SM20210720T patent/SMT202100720T1/it unknown
- 2016-08-04 ES ES16753709T patent/ES2901349T3/es active Active
- 2016-08-04 PL PL16753709T patent/PL3331877T3/pl unknown
- 2016-08-04 KR KR1020187006128A patent/KR102698366B1/ko active Active
- 2016-08-04 CN CN201680059148.XA patent/CN108137562B/zh active Active
- 2016-08-04 CA CA2994644A patent/CA2994644A1/en active Pending
- 2016-08-04 RU RU2018107668A patent/RU2735522C2/ru active
- 2016-08-04 LT LTEPPCT/IL2016/050852T patent/LT3331877T/lt unknown
- 2016-08-04 US US15/748,536 patent/US10376511B2/en active Active
- 2016-08-04 EP EP16753709.1A patent/EP3331877B1/en active Active
- 2016-08-04 AU AU2016304464A patent/AU2016304464B2/en active Active
- 2016-08-04 WO PCT/IL2016/050852 patent/WO2017021969A1/en not_active Ceased
- 2016-08-04 MX MX2018001395A patent/MX384172B/es unknown
- 2016-08-04 HR HRP20211949TT patent/HRP20211949T1/hr unknown
- 2016-08-04 SI SI201631426T patent/SI3331877T1/sl unknown
- 2016-08-04 HU HUE16753709A patent/HUE057607T2/hu unknown
- 2016-08-04 JP JP2018525826A patent/JP7083309B2/ja active Active
-
2018
- 2018-01-31 ZA ZA2018/00671A patent/ZA201800671B/en unknown
- 2018-01-31 IL IL257282A patent/IL257282B/en active IP Right Grant
-
2019
- 2019-08-12 US US16/538,550 patent/US10960003B2/en active Active
-
2021
- 2021-02-10 AU AU2021200839A patent/AU2021200839A1/en not_active Abandoned
- 2021-03-29 US US17/215,959 patent/US11925641B2/en active Active
- 2021-12-21 CY CY20211101124T patent/CY1124898T1/el unknown
-
2024
- 2024-02-05 US US18/432,931 patent/US20250049793A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015058140A1 (en) * | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016304464B2 (en) | Pyrazole pyrimidine derivative and uses thereof | |
| KR102891608B1 (ko) | Irak 분해제 및 이의 용도 | |
| CN115052627A (zh) | Irak降解剂和其用途 | |
| KR20230143632A (ko) | Irak 분해제 및 이의 용도 | |
| CN112105385A (zh) | Irak降解剂和其用途 | |
| US20240025878A1 (en) | Mdm2 degraders and uses thereof | |
| WO2020094104A1 (zh) | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 | |
| CN115776891A (zh) | Stat降解剂和其用途 | |
| CN108602776A (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
| KR20230130179A (ko) | Irak 분해제 및 그 용도 | |
| CN117715904A (zh) | Cdk2降解剂和其用途 | |
| US20240293423A1 (en) | Stat degraders and uses thereof | |
| CN101287728A (zh) | 新的高亲和力噻吩基和呋喃基激酶配体 | |
| KR20190115017A (ko) | 암을 치료하기 위한 ck1 및/또는 irak1 억제제로서의 n1-(4-(5-(사이클로프로필메틸)-1-메틸-1h-피라졸-4-일)피리딘-2-일)사이클로헥산-1,4-디아민 유도체 및 관련 화합물 | |
| CN118973581A (zh) | Irak降解剂及其用途 | |
| CN117881657A (zh) | 苯基-氨磺酰基-苯甲酸衍生物作为erap1调节剂 | |
| HK1256535B (en) | Pyrazole pyrimidine derivative and uses thereof | |
| NZ739511B2 (en) | Pyrazole pyrimidine derivative and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |